Andrey Belousov*, Elena Malygon, Vadim Yavorskiy and Ekateryna Belousova
Department of Anesthesiology, Intensive Care, Transfusiology, Hematology, Kharkov Medical Academy of Postgraduate Education, Ukraine
Submission: August 30, 2018; Published: January 22, 2019
*Corresponding author: Andrey Belousov, Department of Anesthesiology, Intensive Care, Transfusiology and Hematology, Kharkov Medical Academy
Red blood cells (RBCs) transfusion is a critical, life-saving treatment for severe anemia caused by disease or chemotherapy, or by blood loss due to trauma or major surgery. For several decades RBCs components have been prepared as concentrates suspended in nutrient additive solution, which preserves and extends the shelf-life of the RBCs component, allowing up to 6-7 weeks of refrigerated storage . Nevertheless, during storage RBCs undergo a complex and progressive accumulation of physicochemical changes, collectively referred to as the RBCs storage lesion [2,3]. Recent clinical studies have identified RBCs transfusion as an independent risk factor for increased morbidities and mortalities in certain groups of patients, including trauma, cardiac surgery and the critically-ill (reviewed in [4-6]). Additionally, some of these studies have identified that older stored RBCs are more strongly implicated in poorer outcomes compared to fresher RBCs . In order to address these concerns, there is renewed interest to better understand the RBCs storage
lesion and to find ways to ameliorate the deleterious effects of
storage, thereby improving the quality, efficacy and safety of RBCs components for all transfusion recipients.
While increased research effort is being directed to better understand the effects of storage on RBCs and the potential impact on transfusion outcomes , slower progress is being made in finding ways to deter the detrimental effects of the RBCs storage lesion. Over the past 15-20 years, research into the development of new additive …